Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Investigators performed immunohistochemistry on glioblastoma tumor samples in an effort to identify molecular subtypes associated with treatment sensitivities.
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Approval was based on results from two phase 2 single-arm, open-label trials that demonstrated overall response rate and duration of response.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
A vaccine consisting of autologous dendritic cells exposed to tumor antigens was well tolerated and showed clinical benefit among patients with glioblastoma.
Use of dexamethasone was associated with shorter survival in those with glioblastoma treated with a PD-1/PD-L1 inhibitor.
Survival from time of recurrence was similar to that seen in younger patients.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
A new approach combining inducible gene therapy and an anti–PD-1 shows promise in hard-to-treat brain tumors.
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
he designation is supported by data from a phase 1 trial conducted by Reata Pharmaceuticals in 2016. Findings from the study showed 44% of patients treated with berubicin (n=11 out of 25) experienced a statistically significant improvement in progression free survival.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Nivolumab monotherapy fails to improve OS compared to bevacizumab in the treatment of recurrent glioblastoma.
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.